Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes
Part of paid clinical trials in Litchfield Park, Arizona.
- Sponsor
- AstraZeneca
- Study ID
- NCT00736879
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 77 Years
- Healthy Volunteers
- Not accepted
Interventions
- Dapagliflozin — DRUGTablets, Oral, Once Daily, Up to 24 weeks
- Placebo — DRUGTablets, Oral, Once Daily, Up to 24 weeks
Study Details
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on diet and exercise alone. The safety of this treatment will also be studied
Key Dates
- First listed
- Aug 18, 2008
- Start date
- Sep 22, 2008
- Status verified
- Apr 2017
- Primary completion
- Dec 29, 2009
- Completion
- Dec 29, 2009
Study Design
- Enrollment
- 497 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Dapagliflozin 1 mgDapagliflozin: 1 mg
- Experimental: Dapagliflozin 2.5 mgDapagliflozin: 2.5 mg
- Experimental: Dapagliflozin 5 mgDapagliflozin: 5 mg
- Placebo Comparator: PlaceboPlacebo: 0 mg
Primary Outcome Measure
Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Last Observation Carried Forward (LOCF) - All Randomized Participants [ Time Frame: Baseline (Day 1), Week 24 ]
Locations (26)
Find similar trials in Litchfield Park, AZ
By condition
By specialty
Related Studies
- Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)Recruiting · Petter Bjornstad · Aurora, Colorado
- Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney DiseasePHASE3 · Recruiting · Prokidney · Huntsville, Alabama
- An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world ConditionsRecruiting · Bayer · Multiple Locations, New Jersey
- A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.PHASE3 · Not Yet Recruiting · Oramed, Ltd. · Dallas, Texas